ROME, March 19 (Reuters) - The way the public and
institutions have dealt with the AstraZeneca vaccine has
not been "serene", the president of Italian biotech firm IRBM,
which is cooperating with the Anglo-Swedish drugmaker in
developing the shots, said on Friday.
"It is not an exaggeration to say that the treatment
reserved to our vaccine has not been really serene," Piero Di
Lorenzo told daily Corriere della Sera in an interview.
He added that AstraZeneca was making "inhuman" efforts to
organise the production and distribution of its vaccine, but
wasn't making "a cent" by selling it to the European Union at
just under 3 euros per dose.
(Reporting by Giulia Segreti, in redazione a Milano Gianluca
Semeraro)